Antimicrobial Therapy of Selected Bacterial Infections
Steeve Giguère
Search for more papers by this authorSteeve Giguère
Search for more papers by this authorSteeve Giguère DVM, PhD, DACVIM
Professor, Large Animal Internal Medicine
Marguerite Hodgson Chair in Equine Studies, College of Veterinary Medicine, University of Georgia
Search for more papers by this authorJohn F. Prescott MA, VetMB, PhD
Professor
Department of Pathobiology, University of Guelph
Search for more papers by this authorPatricia M. Dowling DVM, MS, DACVIM, DACVCP
Professor, Veterinary Clinical Pharmacology
Veterinary Biomedical Sciences, University of Saskatchewan
Search for more papers by this authorSummary
This chapter discusses special considerations required when treating selected bacterial infections (anaerobic, atypical mycobacterial, Brucella, leptospirosis, mycoplasma, and Nocardia). The selection of antimicrobial agents for the empirical treatment of pure or mixed anaerobic infections is often based on surveillance data at the local or national level. Many anaerobic bacterial infections are mixed, but attempted elimination of all the organisms may not be necessary. This is because the unique synergism that sometimes occurs between aerobic and anaerobic bacteria is such that elimination of only some of the species present in the mixed bacterial infection will result in removal of the synergistic effect and clearance of the infection. The two major approaches to the treatment of anaerobic infections are appropriate antimicrobial therapy and surgical management.
Bibliography
- Brook I. 2011. Anaerobic infections in children. Adv Exp Med Biol 697: 117.
- Stein GE and Goldstein EJ. 2006. Fluoroquinolones and anaerobes. Clin Infect Dis 42: 1598.
- Indiveri MC, Hirsh DC. 1992. Tissues and exudates contain sufficient thymidine for growth of anaerobic bacteria in the presence of inhibitory levels of trimethoprim-sulfamethoxazole. Vet Microbiol 32: 235.
- Jang SS, et al. 1997a. Organisms isolated from dogs and cats with anaerobic infections and susceptibility to selected antimicrobial agents. J Am Vet Med Assoc 210: 1610.
- Jang SS, et al. 1997b. Antimicrobial susceptibilities of equine isolates of Clostridium difficile and molecular characterization of metronidazole-resistant strains. Clin Infect Dis 25:Suppl. 2: S266.
- Nagy E, 2010. Anaerobic infections: update on treatment considerations. Drugs 70: 841.
- Bibliography
- Atkins HS, et al. 2010. Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis against experimental murine Brucella melitensis infection. Int J Antimicrob Agents 36: 66.
- Demirtürk N, et al. 2008. Brucellosis: a retrospective evaluation of 99 cases and review of brucellosis treatment. Trop Doct 38: 59.
- Falagas ME, Bliziotis IA. 2006. Quinolones for treatment of human brucellosis: Critical review of the evidence from microbiological and clinical studies. Antimicrob Agents Chemother 50: 22.
- Garcia-Rodriguez JA, et al. 1991. Lack of effective bactericidal activity of new quinolones against Brucella spp. Antimicrob Agents Chemother 35: 756.
- Hernández-Caselles T, et al. 1989. Treatment of Brucella melitensis infection in mice by use of liposome-encapsulated gentamicin. Am J Vet Res 50: 1486.
- Pappas G, et al. 2005. New approaches to the antibiotic treatment of brucellosis. Int J Antimicrob Agents 26: 101.
- Pappas G. 2010. The changing Brucella ecology: novel reservoirs, new threats. Int J Antimicrob Agents 36 Suppl 1: S8.
- Solera J et al. 1994. Meta-analysis of the efficacy of the combination of rifampicin and doxycycline in the treatment of human brucellosis. Med Clin (Barc) 102: 731.
- Solera J, et al. 1997. Recognition and optimum treatment of brucellosis. Drugs 53: 245.
- Wanke MM, et al. 2006. Use of enrofloxacin in the treatment of canine brucellosis in a dog kennel (clinical trial). Theriogenology 66: 1573.
- Bibliography
- Alangaden GJ, Lerner SA. 1997. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 25: 1213.
- Brown-Elliott BA, et al. 2012. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev. 25: 545.
- Brumbaugh GW, et al. 2004. Susceptibility of Mycobacterium avium subsp. paratuberculosis tomonensin sodium or tilmicosin phosphate in vitro and resulting infectivity in a murine model. Can J Vet Res 68: 175.
- Griffith DE, et al. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175: 367.
- Heifets L. 1996. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob Agents Chemother 40: 1759.
- Hendrick SH, et al. 2006. Efficacy of monensin sodium for the reduction of fecal shedding of Mycobacterium avium subsp. paratuberculosis in infected dairy cattle. Prev Vet Med 75: 206.
- Jogi R, Tyring SK. 2004. Therapy of nontuberculous mycobacterial infections. Derm Therap 17: 491.
- Khardori N, et al. 1994. In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents. Antimicrob Agents Chemother 38: 134.
- Krishnan MY, et al. 2009. Comparison of three methods for susceptibility testing of Mycobacterium avium subsp. paratuberculosis to 11 antimicrobial drugs. J Antimicrob Chemother 64: 310.
- Sweeney et al. 2012. Paratuberculosis (Johne's Disease) in cattle and other susceptible species. J Vet Intern Med doi: 10.1111/j.1939-1676.2012.01019.x.
- Watt B. 1997. In vitro sensitivities and treatment of less common mycobacteria. J Antimicrob Chemother 39: 567.
- Yajko DM, et al. 1996. In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combination of two, three, and four drugs against Mycobacterium avium . Antimicrob Agents Chemother 40: 743.
- Zanetti S, et al. 2006. In vitro activities of antimycobacterial agents against Mycobacterium avium subsp. paratuberculosis linked to Crohn's disease and paratuberculosis. Ann Clin Microbiol Antimicrob 5: 27.
- Bibliography
- Aarestrup FM, Friis NF. 1998. Antimicrobial susceptibility testing of Mycoplasma hyosynoviae isolated from pigs during 1968 to 1971 and during 1995 and 1996. Vet Microbiol 61: 33.
-
Aarestrup FM, Kempf I. 2006. Mycoplasma. In: FM Aarestrup (ed). Antimicrobial Resistance in Bacteria of Animal Origin. Washington, DC: ASM Press, pp. 239–248.
10.1128/9781555817534.ch14 Google Scholar
- Assunção P, et al. 2007. Application of flow cytometry for the determination of minimal inhibitory concentration of several antibacterial agents on Mycoplasma hyopneumoniae . J Appl Microbiol 102: 1132.
- Francoz D, et al. 2005. Determination of Mycoplasma bovis susceptibilities against six antimicrbial agents using the E test method. Vet Microbiol 105: 57.
- Godinho KS. 2008. Susceptibility testing of tulathromycin: Interpretative breakpoints and susceptibility of field isolates. Vet Microbiol 129: 426.
- Godinho KS, et al. 2005. Efficacy of tulathromycin in the treatment of bovine respiratory disease associated with induced Mycoplasma bovis infections in young dairy calves. Vet Ther 6: 96.
- Kobayashi H, et al. 1996. Macrolide susceptibility of Mycoplasma hyorhinis isolated from piglets. Antimicrob Agents Chemother 40: 1030.
- Rosenbusch RF, et al. 2005. In vitro antimicrobial inhibition profiles of Mycoplasma bovis isolates recovered from various regions of the United States from 2002 to 2003. J Vet Diagn Invest 17: 436.
- Thomas A, et al. 2003. Antibiotic susceptibilities of recent isolates of Mycoplasma bovis in Belgium. Vet Rec 153: 428.
- Bibliography
- Ambrosioni J, et al. 2010. Nocardiosis: updated clinical review and experience at a tertiary center. Infection 38: 89.
- Beaman BL, Beaman L. 1994. Nocardia species: Host parasite relationships. Clin Microbiol Rev 7: 213.
- Biberstein EL, et al. 1985. Nocardia asteroides infection in horses: a review. J Am Vet Med Assoc 186: 273.
- Bolan DC, et al. 2004. Equine abortion and premature birth associated with Cellulosimicrobium cellulans infection. J Vet Diagn Invest. 16: 333.
- Conville PS, et al. 2012. Multisite reproducibility of the broth microdilution method for susceptibility testing of Nocardia species. J Clin Microbiol 50: 1270.
- Erol E, et al. 2012. Antibiotic susceptibility patterns of Crossiella equi and Amycolatopsis species causing nocardioform placentitis in horses. J Vet Diagn Invest 24: 1158.
- Labeda DP, etal. 2003. Amycolatopsis kentuckyensis spp. nov., Amycolatopsis lexingtonensis spp. nov. and Amycolatopsis pretoriensis spp. nov., isolated from equine placentas. Int J Syst Evol Microbiol 53: 1601.
- Lai CC, et al. 2009. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J Antimicrob Chemother 64: 73.
- Bibliography
- Alt DP, Bolin CA. 1996. Preliminary evaluation of antimicrobial agents for treatment of Leptospira interrogans serovar pomona infection in hamsters and swine. Am J Vet Res 57: 59.
- Cortese VS, et al. 2007. Evaluation of two antimicrobial therapies in the treatment of Leptospira borgpetersenii serovar hardjo infection in experimentally infected cattle. Vet Ther 8: 201.
- Ellis WA, et al. 1985. Dihydrostreptomycin treatment of bovine carriers of Leptospira interrogans serovar hardjo . Res Vet Sci 39: 292.
- Griffith ME, et al., 2007. Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model. Antimicrob Agents Chemother 51: 2615.
- Ressner RA, et al. 2008. Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira . Antimicrob Agents Chemother 52: 2750.
- Smith CR, et al. 1997. Amoxycillin as an alternative to dihydrostreptomycin sulphate for treating cattle infected with Leptospira borgpetersenii serovar hardjo . Aust Vet J 75: 818.
- Sykes JE, et al. 2011. 2010 ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention. J Vet Intern Med 25: 1.